Combining Charge-Shielding & Hydrophobicity-Masking Linker Technologies with Orthogonal Design to Enhance Tumor Selectivity & Target Efficacy
- Evaluating orthogonal versus linear linker architectures to demonstrate superior in vivo efficacy and therapeutic index enabled by controlled, multi-stage drug release at the tumor site
- Comparing traditional PEGylated linkers with novel Polysarcosine (PSAR)-based shielding technologies to optimize the hydrophilicity-masking balance, minimizing offtarget interactions while maintaining favorable pharmacokinetics
- Presenting proof-of-concept data for a tumor-selective linker design, where enzymatic cleavage within the microenvironment precisely exposes the cytotoxic payload, enhancing therapeutic specificity and safety